About VenatoRx Pharmaceuticals
Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of antibiotic products to combat the increasing threat of carbapenem antibiotic resistance. VenatoRx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, and a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature